Role of nitric oxide synthase inhibitors and NMDA receptor antagonist in nicotine-induced behavioral sensitization in the rat

• Published in: European journal of pharmacology 2002-05, Vol.443 (1), p.119-124
• Main Authors: Shim, Insop, Kim, Hyun-Taek, Kim, Young-Ho, Chun, Boe-Gwun, Hahm, Dae-Hyun, Lee, Eunjoo H., Kim, Sang Eun, Lee, Hye-Jung
• Format: Article
• Language: English
• Subjects: Animals; Behavior, Animal - drug effects; Behavioral sensitization; Biological and medical sciences; Dizocilpine Maleate - pharmacology; Enzyme Inhibitors - pharmacology; Excitatory Amino Acid Antagonists - pharmacology; Male; Medical sciences; Motor Activity - drug effects; Nicotine; Nicotine - pharmacology; Nitric oxide (NO); Nitric Oxide - antagonists & inhibitors; Nitric Oxide - physiology; Nitric Oxide Synthase - antagonists & inhibitors; Nitric Oxide Synthase Type II; NMDA receptor; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors; Tobacco, tobacco smoking; Toxicology
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/S0014-2999(02)01582-0

Repeated injections of nicotine are well known to produce progressively larger increases in locomotor activity, an effect defined as behavioral sensitization. This study was carried out to investigate the role of nitric oxide (NO) and N-methyl- d-aspartate (NMDA) receptors in nicotine-induced behavioral sensitization. Rats were given repeated injections of nicotine (0.4 mg/kg, s.c., twice daily for 7 days) followed by one challenge injection on the fourth day after the last daily injection. Systemic challenge with nicotine produced a much larger increase in locomotor activity in nicotine-pretreated rats. Rats were pretreated with the nonselective nitric oxide synthase (NOS) inhibitor, N G-nitro-arginine-methyl-ester ( l-NAME; 75 mg/kg, i.p.), the selective constitutive NOS inhibitor, N-nitro- l-arginine ( l-NNA; 15 mg/kg, i.p.), the prototypical selective inducible NOS inhibitor, aminoguanidine (100 mg/kg, i.p.) or NMDA receptor antagonist, MK-801 ((5 R,10 S)-(+)-5-Methyl-10,11-dihydro-5 H-dibenzo[a,d] cyclohepten-5,10-imine; 0.3 mg/kg, i.p.), 30 min before injections of nicotine during a 7-day development or a 3-day withdrawal phase after which challenged with nicotine on day 11. Pretreatment with l-NAME, l-NNA and MK-801, but not aminoguanidine, blocked the development of nicotine-induced sensitization to subsequent nicotine challenge. Injections of MK-801 twice daily during 3-day withdrawal periods after a 7-day induction period of nicotine attenuated nicotine-induced behavioral sensitization, whereas injections of l-NAME, l-NNA or aminoguanidine had no effects on the expression of sensitization produced by repeated nicotine. This study demonstrates that NMDA receptors can play a major role in the expression as well as development of nicotine-induced behavioral sensitization, and that NO is also involved in the development, but not critically involved in the expression of behavioral sensitization to nicotine.